The purpose of this study is determine if subjects with alcohol withdrawal who receive oral
baclofen, plus standard benzodiazepine therapy, will experience less severe withdrawal
symptoms than those who receive placebo plus standard benzodiazepine therapy.Subjects with
alcohol withdrawal syndrome(AWS)who receive baclofen plus standard benzodiazepine therapy
will experience fewer complications of AWS (as measured by use of additional sedatives,
restraints, and/or intensive care unit [ICU] admissions) compared with subjects who receive
placebo plus standard benzodiazepine therapy.